
Nianxiang Zou
Examiner (ID: 10628, Phone: (571)272-2850 , Office: P/1648 )
| Most Active Art Unit | 1648 |
| Art Unit(s) | 1648, 1671 |
| Total Applications | 845 |
| Issued Applications | 504 |
| Pending Applications | 89 |
| Abandoned Applications | 294 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19310485
[patent_doc_number] => 12036279
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-16
[patent_title] => Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
[patent_app_type] => utility
[patent_app_number] => 17/681342
[patent_app_country] => US
[patent_app_date] => 2022-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 44
[patent_figures_cnt] => 63
[patent_no_of_words] => 28217
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17681342
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/681342 | Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors | Feb 24, 2022 | Issued |
Array
(
[id] => 17641967
[patent_doc_number] => 20220169705
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-02
[patent_title] => TOPICAL APPLICATION FOR AN ANTI-HSV ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 17/675329
[patent_app_country] => US
[patent_app_date] => 2022-02-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20037
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17675329
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/675329 | TOPICAL APPLICATION FOR AN ANTI-HSV ANTIBODY | Feb 17, 2022 | Pending |
Array
(
[id] => 17807845
[patent_doc_number] => 20220259680
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-18
[patent_title] => SARS CoV-2 INFECTIVITY DETERMINATION ASSAY
[patent_app_type] => utility
[patent_app_number] => 17/670811
[patent_app_country] => US
[patent_app_date] => 2022-02-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8662
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 96
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17670811
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/670811 | SARS CoV-2 INFECTIVITY DETERMINATION ASSAY | Feb 13, 2022 | Abandoned |
Array
(
[id] => 18747141
[patent_doc_number] => 11806432
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-11-07
[patent_title] => Compositions, methods and uses for thermally stable multi-targeted antigens
[patent_app_type] => utility
[patent_app_number] => 17/665285
[patent_app_country] => US
[patent_app_date] => 2022-02-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 29
[patent_no_of_words] => 14785
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 126
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17665285
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/665285 | Compositions, methods and uses for thermally stable multi-targeted antigens | Feb 3, 2022 | Issued |
Array
(
[id] => 17705992
[patent_doc_number] => 20220205998
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-30
[patent_title] => ASSAY FOR NEUTRALIZING ANTIBODY TESTING AND TREATMENT
[patent_app_type] => utility
[patent_app_number] => 17/590353
[patent_app_country] => US
[patent_app_date] => 2022-02-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12329
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 85
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17590353
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/590353 | ASSAY FOR NEUTRALIZING ANTIBODY TESTING AND TREATMENT | Jan 31, 2022 | Abandoned |
Array
(
[id] => 17593597
[patent_doc_number] => 20220143170
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-12
[patent_title] => COMPOSITIONS, METHODS AND USES FOR THERMALLY STABLE HUMAN PAPILLOMAVIRUS FORMULATIONS
[patent_app_type] => utility
[patent_app_number] => 17/587953
[patent_app_country] => US
[patent_app_date] => 2022-01-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11334
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 102
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17587953
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/587953 | COMPOSITIONS, METHODS AND USES FOR THERMALLY STABLE HUMAN PAPILLOMAVIRUS FORMULATIONS | Jan 27, 2022 | Abandoned |
Array
(
[id] => 17851882
[patent_doc_number] => 20220281924
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-08
[patent_title] => ENGINEERED HEPATITIS B CORE POLYPEPTIDE
[patent_app_type] => utility
[patent_app_number] => 17/581655
[patent_app_country] => US
[patent_app_date] => 2022-01-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18460
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17581655
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/581655 | ENGINEERED HEPATITIS B CORE POLYPEPTIDE | Jan 20, 2022 | Abandoned |
Array
(
[id] => 18510066
[patent_doc_number] => 20230226164
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-20
[patent_title] => VACCINE COMBINATION AND METHOD FOR USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 17/578312
[patent_app_country] => US
[patent_app_date] => 2022-01-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6385
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 337
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17578312
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/578312 | Vaccine combination and method for using the same | Jan 17, 2022 | Issued |
Array
(
[id] => 18510066
[patent_doc_number] => 20230226164
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-20
[patent_title] => VACCINE COMBINATION AND METHOD FOR USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 17/578312
[patent_app_country] => US
[patent_app_date] => 2022-01-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6385
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 337
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17578312
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/578312 | Vaccine combination and method for using the same | Jan 17, 2022 | Issued |
Array
(
[id] => 18903953
[patent_doc_number] => 20240019438
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-18
[patent_title] => ASSAYS FOR RAPID DETECTION OF AIRBORNE VIRUSES INCLUDING INFLUENZA AND CORONAVIRUSES
[patent_app_type] => utility
[patent_app_number] => 18/256844
[patent_app_country] => US
[patent_app_date] => 2021-12-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18262
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18256844
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/256844 | ASSAYS FOR RAPID DETECTION OF AIRBORNE VIRUSES INCLUDING INFLUENZA AND CORONAVIRUSES | Dec 30, 2021 | Pending |
Array
(
[id] => 18903953
[patent_doc_number] => 20240019438
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-18
[patent_title] => ASSAYS FOR RAPID DETECTION OF AIRBORNE VIRUSES INCLUDING INFLUENZA AND CORONAVIRUSES
[patent_app_type] => utility
[patent_app_number] => 18/256844
[patent_app_country] => US
[patent_app_date] => 2021-12-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18262
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18256844
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/256844 | ASSAYS FOR RAPID DETECTION OF AIRBORNE VIRUSES INCLUDING INFLUENZA AND CORONAVIRUSES | Dec 30, 2021 | Pending |
Array
(
[id] => 17881214
[patent_doc_number] => 20220296691
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-22
[patent_title] => METHODS FOR TREATING CANCER WITH ACTIVATING ANTIGEN CARRIERS
[patent_app_type] => utility
[patent_app_number] => 17/563787
[patent_app_country] => US
[patent_app_date] => 2021-12-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49562
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17563787
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/563787 | METHODS FOR TREATING CANCER WITH ACTIVATING ANTIGEN CARRIERS | Dec 27, 2021 | Pending |
Array
(
[id] => 18986467
[patent_doc_number] => 20240058436
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-22
[patent_title] => MULTIVALENT HVT VECTOR VACCINE
[patent_app_type] => utility
[patent_app_number] => 18/257889
[patent_app_country] => US
[patent_app_date] => 2021-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15452
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18257889
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/257889 | MULTIVALENT HVT VECTOR VACCINE | Dec 22, 2021 | Pending |
Array
(
[id] => 17563159
[patent_doc_number] => 20220127308
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-28
[patent_title] => Desmoglein 2 (DSG2) Binding Proteins and Uses Therefor
[patent_app_type] => utility
[patent_app_number] => 17/559391
[patent_app_country] => US
[patent_app_date] => 2021-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28372
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17559391
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/559391 | Desmoglein 2 (DSG2) binding proteins and uses therefor | Dec 21, 2021 | Issued |
Array
(
[id] => 19179963
[patent_doc_number] => 11986538
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-05-21
[patent_title] => Immunoswitch nanoparticles for reprogrammed T cell responses
[patent_app_type] => utility
[patent_app_number] => 17/557886
[patent_app_country] => US
[patent_app_date] => 2021-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 50
[patent_no_of_words] => 36682
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 88
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17557886
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/557886 | Immunoswitch nanoparticles for reprogrammed T cell responses | Dec 20, 2021 | Issued |
Array
(
[id] => 19154208
[patent_doc_number] => 11979133
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-05-07
[patent_title] => Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 17/556816
[patent_app_country] => US
[patent_app_date] => 2021-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 17
[patent_no_of_words] => 20717
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 114
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17556816
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/556816 | Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites and methods of use thereof | Dec 19, 2021 | Issued |
Array
(
[id] => 17777908
[patent_doc_number] => 20220244258
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-04
[patent_title] => Assay For Neutralizing Antibody Testing And Treatment
[patent_app_type] => utility
[patent_app_number] => 17/300929
[patent_app_country] => US
[patent_app_date] => 2021-12-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12184
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 83
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17300929
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/300929 | Assay For Neutralizing Antibody Testing And Treatment | Dec 15, 2021 | Abandoned |
Array
(
[id] => 17775052
[patent_doc_number] => 20220241401
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-04
[patent_title] => VACCINES AGAINST GENITAL HERPES SIMPLEX INFECTIONS
[patent_app_type] => utility
[patent_app_number] => 17/550272
[patent_app_country] => US
[patent_app_date] => 2021-12-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16038
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17550272
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/550272 | VACCINES AGAINST GENITAL HERPES SIMPLEX INFECTIONS | Dec 13, 2021 | Abandoned |
Array
(
[id] => 17609910
[patent_doc_number] => 20220152189
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-19
[patent_title] => HPV VACCINE
[patent_app_type] => utility
[patent_app_number] => 17/532177
[patent_app_country] => US
[patent_app_date] => 2021-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12697
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17532177
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/532177 | HPV vaccine | Nov 21, 2021 | Issued |
Array
(
[id] => 19249166
[patent_doc_number] => 20240200153
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => CROSS PRIMER ISOTHERMAL AMPLIFICATION PRIMER SET FOR DETECTING TOBACCO RINGSPOT VIRUS, KIT AND APPLICATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/529206
[patent_app_country] => US
[patent_app_date] => 2021-11-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4887
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 122
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17529206
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/529206 | CROSS PRIMER ISOTHERMAL AMPLIFICATION PRIMER SET FOR DETECTING TOBACCO RINGSPOT VIRUS, KIT AND APPLICATION THEREOF | Nov 16, 2021 | Abandoned |